NFATC4 and cardiac hypertrophy: Fenofibrate attenuates pressure overload-induced cardiac hypertrophy partly by inhibiting the binding of p65-NFκB to NFATc4, the c-Jun NH2-terminal kinase pathway, ERK activation, and MMP2 activity, as well as increasing high mobility group box 1 (HMGB1) levels in nuclei [12, 15, 33, 34].